This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose tacrolimus, and corticosteroids appeared to be the most effective with respect to the glomerular filtration rate, allograft survival, and acute rejection, as compared with regimens containing dacluzimab induction plus either low-dose cyclosporine or low-dose sirolimus and with standard-dose cyclosporine without induction. A regimen containing mycophenolate mofetil, daclizumab, low-dose tacrolimus, and corticosteroids appeared to be the most effective with respect to the glomerular filtration rate, allograft survival, and acute rejection. Despite improved short-term outcome in renal transplantation, 3 to 5% of allografts per year are still lost; the leading causes are long-term allograft nephropathy and death with a functioning allograft. 1 As patients have fewer acute rejection episodes, adverse events associated with long-term immunosuppression have become increasingly evident. Accordingly, reducing the toxic effects of immunosuppressive regimens has become a major goal in the treatment of transplant recipients. Cyclosporine, a calcineurin inhibitor in use for many years, is still the basis of many immunosuppressive regimens because of its clinical success. However, standard recommended doses are associated with nephrotoxicity, resulting in long-term renal . . .